On Friday, CytomX Therapeutics Inc (NASDAQ: CTMX) opened lower -4.63% from the last session, before settling in for the closing price of $1.08. Price fluctuations for CTMX have ranged from $1.04 to $5.85 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 28.25% over the past five years. Company’s average yearly earnings per share was noted -3053.00% at the time writing. With a float of $76.79 million, this company’s outstanding shares have now reached $78.12 million.
Let’s look at the performance matrix of the company that is accounted for 122 employees. In terms of profitability, gross margin is 97.63%, operating margin of 4.79%, and the pretax margin is 12.61%.
CytomX Therapeutics Inc (CTMX) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of CytomX Therapeutics Inc is 1.69%, while institutional ownership is 72.85%. The most recent insider transaction that took place on Aug 20 ’24, was worth 5,139. In this transaction Chief Business Officer of this company sold 4,181 shares at a rate of $1.23, taking the stock ownership to the 119,056 shares. Before that another transaction happened on Aug 20 ’24, when Company’s SVP, Chief Scientific Officer sold 4,181 for $1.23, making the entire transaction worth $5,139. This insider now owns 175,648 shares in total.
CytomX Therapeutics Inc (CTMX) Latest Financial update
If we go through the results of last quarter, which was made public on 6/30/2024, the company posted 0.04 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.19) by 0.23. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.2 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -3053.00% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -0.90% during the next five years compared to 67.21% growth over the previous five years of trading.
CytomX Therapeutics Inc (NASDAQ: CTMX) Trading Performance Indicators
Check out the current performance indicators for CytomX Therapeutics Inc (CTMX). In the past quarter, the stock posted a quick ratio of 1.00. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.67.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.14, a number that is poised to hit -0.17 in the next quarter and is forecasted to reach -0.61 in one year’s time.
Technical Analysis of CytomX Therapeutics Inc (CTMX)
CytomX Therapeutics Inc (NASDAQ: CTMX) saw its 5-day average volume 0.88 million, a negative change from its year-to-date volume of 2.63 million. As of the previous 9 days, the stock’s Stochastic %D was 9.87%. Additionally, its Average True Range was 0.06.
During the past 100 days, CytomX Therapeutics Inc’s (CTMX) raw stochastic average was set at 1.41%, which indicates a significant decrease from 5.88% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 49.14% in the past 14 days, which was lower than the 56.45% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.1772, while its 200-day Moving Average is $1.6477. Nevertheless, the first resistance level for the watch stands at $1.0733 in the near term. At $1.1167, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.1433. If the price goes on to break the first support level at $1.0033, it is likely to go to the next support level at $0.9767. The third support level lies at $0.9333 if the price breaches the second support level.
CytomX Therapeutics Inc (NASDAQ: CTMX) Key Stats
There are currently 77,919K shares outstanding in the company with a market cap of 80.46 million. Presently, the company’s annual sales total 101,210 K according to its annual income of -570 K. Last quarter, the company’s sales amounted to 25,120 K and its income totaled -6,530 K.
